Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension.
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2012
At a glance
- Drugs CYT 006 AngQb (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Cytos Biotechnology
- 31 Aug 2018 Biomarkers information updated
- 24 Jun 2009 Cytos Biotechnology has reported the results of a biochemical analysis of this trial in a company media release.
- 17 Mar 2009 Secondary endpoint 'Ambulatory blood pressure' has not been met.